» Articles » PMID: 20876637

Head and Neck Cancer--Part 2: Treatment and Prognostic Factors

Overview
Journal BMJ
Specialty General Medicine
Date 2010 Sep 30
PMID 20876637
Citations 32
Authors
Affiliations
Soon will be listed here.
Citing Articles

Boosting Antioxidant Defense: The Effect of Astaxantin on Superoxidase Dismutase and Malondialdehyde Reduction in Patients with Head and Neck Cancer Receiving Cisplatin Chemotherapy.

Aminullah Y, Naftali Z, Santosa D, Prajoko Y, Azam M, Susanto H Asian Pac J Cancer Prev. 2024; 25(10):3741-3748.

PMID: 39487992 PMC: 11711335. DOI: 10.31557/APJCP.2024.25.10.3741.


Deep learning-enabled fluorescence imaging for surgical guidance: training for oral cancer depth quantification.

Won N, Bartling M, La Macchia J, Markevich S, Holtshousen S, Jagota A J Biomed Opt. 2024; 30(Suppl 1):S13706.

PMID: 39295734 PMC: 11408754. DOI: 10.1117/1.JBO.30.S1.S13706.


Subsite-specific trends in mid- and long-term survival for head and neck cancer patients in Japan: A population-based study.

Tsuge H, Kawakita D, Taniyama Y, Oze I, Koyanagi Y, Hori M Cancer Sci. 2023; 115(2):623-634.

PMID: 37994633 PMC: 10859624. DOI: 10.1111/cas.16028.


Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.

Limkin E, Blanchard P, Lacas B, Bourhis J, Parmar M, Licitra L Radiother Oncol. 2023; 190:110011.

PMID: 37956890 PMC: 11253287. DOI: 10.1016/j.radonc.2023.110011.


DNA damage response and potential biomarkers of radiosensitivity in head and neck cancers: clinical implications.

Carpov D, Buiga R, Nagy V Rom J Morphol Embryol. 2023; 64(1):5-13.

PMID: 37128786 PMC: 10257787. DOI: 10.47162/RJME.64.1.01.